Aktienanalyse zu Pulse Biosciences Inc (PLSE)PLSEPulse Biosciences Inc

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Pulse Biosciences Inc is a good buy right now due to its current price of $53.02, a strong year-to-date change of +295.97%, and a positive analyst price target of $73, which suggests significant upside potential. The RSI is at 67.796, indicating bullish momentum, while the stock has shown a robust 5-day change of +19.33%. However, the main risk is its negative earnings per share (EPS) of -0.36, which reflects ongoing losses and uncertainty in profitability.